5-Amino-1MQ

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small molecule compound currently under investigation for its potential role in metabolic health and weight management. As a selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), this compound represents an innovative approach to addressing metabolic dysfunction by targeting cellular energy pathways at their source.

Unlike traditional weight loss interventions that primarily focus on caloric restriction or appetite suppression, 5-Amino-1MQ works at the cellular level to influence how the body produces and utilizes energy. This compound has garnered significant attention in both research and clinical communities for its unique mechanism of action and promising preclinical results.

Targeting NNMT
NNMT is an enzyme found primarily in fat tissue and liver that methylates nicotinamide (vitamin B3) using S-adenosyl-methionine (SAM), producing methylnicotinamide (MNAM). Research shows NNMT expression increases with age and obesity, contributing to reduced cellular energy, increased fat accumulation, and impaired glucose metabolism.
5-Amino-1MQ acts as a nicotinamide analog, competitively binding to NNMT’s active site and blocking its activity without affecting other metabolic enzymes.

The NAD+ Connection
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for:

• Mitochondrial energy production
• DNA repair
• Metabolic regulation of fats, carbohydrates, and proteins

When NNMT methylates nicotinamide, it depletes the substrate needed for NAD+ synthesis via the salvage pathway (~85% of NAD+ production). Lower NAD+ leads to reduced energy expenditure, impaired fat oxidation, and metabolic dysfunction.

By inhibiting NNMT, 5-Amino-1MQ preserves nicotinamide availability, supporting optimal NAD+ levels and the metabolic processes depending on it.

Cellular Effects of 5-Amino-1MQ:

• Increased Energy Expenditure: Significantly higher oxygen consumption in fat cells
• Reduced Fat Formation: Suppressed lipogenesis in adipocytes
• Enhanced Polyamine Flux: Increased energy consumption through acetyl-CoA utilization
• Adipocyte Size Reduction: Actual fat mobilization, not just prevention of storage
• Gene Expression Changes: Modified expression of gluconeogenesis enzymes

A landmark 2018 study in Biochemical Pharmacology demonstrated that mice with diet-induced obesity treated with 5-Amino-1MQ showed:

• 5.1% weight loss over 11 days (vs. 1.4% gain in controls)
• ~35% reduction in white adipose tissue mass
• ~30% decrease in adipocyte size
• ~30% reduction in plasma cholesterol
• Improved glucose tolerance and insulin sensitivity
• No effect on food intake (metabolic, not appetite-driven)
• No observable adverse effects

The compound demonstrated high selectivity for NNMT, excellent cell membrane permeability, and did not inhibit other methyltransferases or NAD+ pathway enzymes.

Mechanism Confirmation:

• Reduces intracellular MNAM (confirming NNMT inhibition)
• Increases NAD+ levels by ~30%
• Suppresses adipogenesis
• Prevents preadipocyte differentiation into fat-storing cells

Current Research Status:

• As of December 2024, 5-Amino-1MQ has not undergone human clinical trials and is not FDA-approved.
• All efficacy and safety data come exclusively from animal studies and cellular research.
• Classified as a research chemical; long-term human safety is unknown.

Potential Applications Being Studied:

• Metabolic Syndrome & Obesity: Targeting multiple metabolic dysfunctions simultaneously
• Type 2 Diabetes: Improving glucose tolerance and insulin sensitivity
• Age-Related Metabolic Decline: Counteracting increased NNMT expression with aging
• Cardiovascular Health: Exploring benefits related to NNMT’s effects on homocysteine and lipid metabolism

Important Considerations:

• Not Approved: 5-Amino-1MQ is not FDA-approved for any medical use
• Quality Unknown: Commercially available products may lack pharmaceutical-grade quality standards
• Safety Uncertain: Human dosing, side effects, contraindications, and long-term safety are undetermined

Primary Research Study

• Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141-152.
• Lead Author: Hari Neelakantan, University of Texas Medical Branch at Galveston
• Senior Author: Stanley J. Watowich, PhD, Professor of Biochemistry & Molecular Biology, University of Texas Medical Branch

Comprehensive Review

• Sun W-D, et al. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. Frontiers in Pharmacology. 2024;15:1410479.
• Lead Author: Wen-Dong Sun
• Senior Author: Jia-Hai Li, PhD

This content is for educational purposes only and does not constitute medical advice. 5-Amino-1MQ is not approved for human use.